Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B generates €27.5mm for arGEN-X BV; adds €5mm

Executive Summary

Dutch antibody therapeutics developer arGEN-X BV has raised €27.5mm ($37mm) through its oversubscribed Series B financing led by new investors OrbiMed Advisors (added a board member) and Seventure Partners, which were joined by returning shareholders Forbion Capital Partners, Credit Agricole Private Equity, Life Sciences Partners, BioGeneration Ventures, Erasmus Biomedical Fund, Thuja Capital, and Flemish research institute VIB. Funds will support ongoing development of antibodies based on its SIMPLE Antibody platform. The company raised €12.5mm via its Series A round in 2009.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies